Trial Profile
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure. GLUCOSUR-IC Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms GLUCOSUR-IC
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 06 Sep 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 06 Sep 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.